In a recent development, a Delaware federal judge has dismissed 10 of the14 originally asserted patents from Mallinckrodt, a globally recognized pharmaceutical company, in a lawsuit against a French industrial gas company. Mallinckrodt alleges the French company is infringing on its intellectual property rights by producing a generic version of its pediatric breathing disorder treatment.
The scope of the lawsuit has notably shifted as Mallinckrodt, responding to the dismissals, filed an amended complaint in which it adds two new patents to the suit. These developments in the case can be seen as an indicator of the complexities inherent to intellectual property rights litigation, particularly within the pharmaceutical sector where patent protection plays a crucial role in maintaining competitiveness.
The named pharmaceutical treatment at the center of this dispute is a crucial drug for managing pediatric breathing disorders. The introduction of a generic version by the French Industrial gas company could potentially impact the market dynamics of this medication, depending on the progress and outcome of this ongoing lawsuit.
For more in-depth details about this case, you can learn more at the original legal briefing on Law360.